BiologicalDrug
Lumrotatug clinical trials
Also written CM313.
Keep track of what changes. Save the lumrotatug studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Keymed Biosciences Co.Ltd (9) · Institute of Hematology & Blood Diseases Hospital, China (2) · Sichuan Provincial People's Hospital (1) · Chao Ji (1)
Studies
Open first, then newest update. How each study uses lumrotatug is read from its arms, and is right about nine times in ten.
Testing it · 13
- Study of CM313 in Subject With IgA NephropathyNot yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06830395Written as CM313
- Study of CM313(SC) Injection in Subjects With Platelet Transfusion RefractorinessRecruitingPhase 1/2Keymed Biosciences Co.LtdNCT06792019Written as CM313(SC) injection-low dose
- A Single-center Study of CM313 in Patients With PemphigusNot yet recruitingNot applicableSichuan Provincial People's HospitalNCT06904040Written as CM313 injection
- Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic AnemiaNot yet recruitingPhase 1/2Keymed Biosciences Co.LtdNCT06791824Written as CM313(SC) injection
- Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)Not yet recruitingPhase 2Keymed Biosciences Co.LtdNCT06791772Written as CM313 injection
- A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.Not yet recruitingPhase 1/2Chao JiNCT06663943Written as CM313 (SC)
- Study of CM313 in Healthy SubjectsRecruitingPhase 1Keymed Biosciences Co.LtdNCT06285227Written as CM313 injection
- A Study of CM313 in Subjects With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 1/2Keymed Biosciences Co.LtdNCT06126237Written as CM313 injection
- Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)Active, not recruitingPhase 2Keymed Biosciences Co.LtdNCT06594146Written as CM313 injection
- A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaCompletedPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT05694767Written as CM313 Injection
- A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaActive, not recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06199089Written as CM313 Injection
- A Study of CM313 Injection in Subjects With Systemic Lupus ErythematosusStatus unknownPhase 1/2Keymed Biosciences Co.LtdNCT05465707Written as CM313 2 mg/kg
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownPhase 1Keymed Biosciences Co.LtdNCT04818372Written as CM313-Dose escalation
Codes
What other systems call lumrotatug · ClinicalTrials.gg INT016702
- UNII (FDA) GT2R696LEMLUMROTATUGOne source FDA
- NCI Thesaurus C180505LumrotatugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | GT2R696LEM | LUMROTATUG | One source FDA |
| NCI Thesaurus | C180505 | Lumrotatug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.